Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Zacks News
Here is Why Growth Investors Should Buy Merck (MRK) Now
by Zacks Equity Research
Merck (MRK) possesses solid growth attributes, which could help it handily outperform the market.
Are Investors Undervaluing Innoviva (INVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Cheers Soft Inflation Data: 5 Growth Picks
by Tirthankar Chakraborty
Invest in growth stocks like Murphy USA (MUSA), Merck (MRK) & New Fortress Energy (NFE), to name a few, as Wall Street rises on signs of cooling inflation.
AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up
by Zacks Equity Research
AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged.
Mirati's (MRTX) Stock Rises on Q3 Earnings and Sales Beat
by Zacks Equity Research
Mirati Therapeutics (MRTX) reports narrower-than-expected Q3 loss. Revenues also beat the mark. Stock rises in after-hours trading.
Merck & Co., Inc. (MRK) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Merck (MRK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook
by Zacks Equity Research
Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.
Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Bayer's (BAYRY) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
The Zacks Analyst Blog Highlights Merck, ConocoPhillips, Adobe, Intercontinental Exchange and Monster Beverage
by Zacks Equity Research
Merck, ConocoPhillips, Adobe, Intercontinental Exchange and Monster Beverage are included in this Analyst Blog.
Top Research Reports for Merck, ConocoPhillips & Adobe
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), ConocoPhillips (COP) and Adobe Inc. (ADBE).
AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) third-quarter 2022 earnings beat estimates while revenues miss the same. The company tightens its revenue guidance for 2022. Shares down in after-hours trading.
Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook
by Zacks Equity Research
Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.
Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.
Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.
Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights Caterpillar, JPMorgan Chase, Home Depot and Merck & Co
by Zacks Equity Research
Caterpillar, JPMorgan Chase, Home Depot and Merck & Co. are part of the Zacks top Analyst Blog.
Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View
by Zacks Equity Research
Eli Lilly's (LLY) earnings and sales surpass third-quarter estimates. The company lowers 2022 financial view for the third time this year. The stock falls in pre-market trading.
4 Blue-Chip Stocks to Buy as Dow Seals Record October Gains
by Tirthankar Chakraborty
With the Dow witnessing a sharp run-up in October, investing in stocks like Caterpillar (CAT), JPMorgan (JPM), Home Depot (HD) and Merck (MRK) seems prudent.
Merck (MRK) Upgraded to Buy: Here's Why
by Zacks Equity Research
Merck (MRK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.